FDA's Center for Drug Evaluation & Research: 2015 Priorities & Accomplishments

December 16, 2015

FDA's Center for Drug Evaluation & Research (CDER) 2015 Priorities & Accomplishments

Front Burner Priorities:

  • GDUFA: meeting and exceeding performance goals; confident the division can reach steady state in two years
  • Stabilization of new Office of Generic Drugs: accomplished
  • Standup of Office of Pharmaceutical Quality: completed
  • Completion of 2015 PAG agreement work: done
  • Pharmacy compounding:
    • Establishment of AC; multiple meetings
    • Multiple draft and final Guidances issued
  • Standup of Panorama (new IT system for workflow management, document and data access): accomplished--generic drug review process running on Panorama
  • Respond to Sunscreen Innovation Act: have met all milestones
  • Abuse-Deterrent Opioids Final Guidance: Issued 4/15
  • Respond to Congressional requests on “21st Century Cures” legislation: done

Important Priorities:

  • Established Sentinel Network in OSE: intent to utilize in routine drug safety activities
  • OTC monograph reform: discussion of new approach with Congress and industry ongoing
  • Sustainable model for ICH: completed, initial technical meeting held last week
  • Biosimilars Program:
  • Posting demographic information about newly approved drugs: “Drug Snapshots” program established
  • Important guidances issued (many), for example:
  • Build in-house OD capacity: New CDER leadership development program established
  • GLP testing oversight function: established in OTS
  • Management: implementation of LIRA, new budget management system

As stated by Janet Woodcock, MD, Director of CDER, at the FDA/CMS Summit for Biopharma Executives on December 14, 2015.


December 16, 2015

FDA’s Center for Drug Evaluation & Research: 2016 Priorities

FDA’s Center for Drug Evaluation & Research (CDER) 2016 Priorities & Areas of Focus Front Burner Priorities: Negotiate PDUFA 6 agreements Negotiate GDUFA 2 agreements Negotiate a second BSUFA program...

December 16, 2015

Woodcock Announces CDER’s 2016 Priorities & Says ANDA Backlog was the Biggest Challenge of GDUFA I

On Monday, December 14th, the director of FDA's Center for Drug Evaluation and Research (CDER), Janet Woodcock, M.D., spoke at the FDA/CMS Summit for Biopharma Executives where she announced the...

January 27, 2016

FDA's CDER Announces New & Revised Draft Guidances it Plans to Publish in 2016

On Friday, January 22, FDA’s Center for Drug Evaluation and Research (CDER) published its 2016 guidance agenda. The guidance agenda is published on an annual basis and announces the draft guidances...